drugset / Trial / NCT05564221
A Multiple Ascending Dose, Phase 1b Study of YH35324 in Atopic Healthy Subjects or Subjects With Allergic Diseases
RandomizedParallel-groupQuadruple-blindTreatment
Summary
This study aims to evaluate the safety, tolerability, pharmacokinetic (PK) and pharmacodynamic (PD) profiles following multiple subcutaneous injections of YH35324 in healthy subjects or subjects with allergic diseases, who have atopy.
Timeline
- Start
- 2022-11-01
- Primary completion
- 2024-11-28
- Completion
- 2024-11-28
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Omalizumab | Monoclonal antibody | 300 mg | Subcutaneous |
| Subject | YH35324 | Unknown | — | Subcutaneous |